📉 Novo Nordisk just took a massive hit. After slashing its full-year guidance and warning of weaker U.S. Wegovy sales, shares dropped 23%—wiping out billions in market value. With a new CEO stepping in Aug. 7, is this the beginning of a pharma reset… or is the weight-loss drug bubble finally bursting? Will the competition catch up? Can Novo recover? Full Q2 earnings drop Aug. 6. Stay tuned. #NovoNordisk #Wegovy #StockMarket